Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FIRST-2.5: Finerenone Research of Early Safety and Effectiveness, Part 2.5

NCT06608212 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06608212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06608212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FIRST-2.5: Finerenone Research of Early Safety and Effectiveness, Part 2.5
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
October 9, 2024
Completion date
June 26, 2026
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, type 2 diabetes mellitus